Biotech boss urges pharma to move on from ‘weight-loss Olympics’
Zealand Pharma chief says next-generation obesity drugs will need to be longer lasting and better tolerated
Related reading
Biotech group’s shares hit by weight-loss drug setback
Zealand Pharma falls 32% following mid-stage trial results for treatment being developed with Roche
The race to launch a pill for weight loss
Despite success with injectable drugs pharma companies are investing heavily in tablets, long considered the holy grail of…
Pharma just ‘scratching the surface’ of weight-loss drug market
Novo Nordisk chief estimates industry reaching only 15% of potential customers at most
Eli Lilly wins US approval for weight-loss drug in pill form
New drug Foundayo sets up battle with Novo Nordisk for oral obesity drugs
Weight-loss wars: $10bn hostile battle pits Pfizer against Novo Nordisk
Two groups fight for edge in one of the most lucrative drug classes in pharmaceutical industry history
Eli Lilly shot helped patients lose 29% of body weight
Trial results are a boost to US pharmaceutical company’s booming obesity business